UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2022
Commission File Number: 001-39545
Orphazyme A/S
(Translation of registrant’s name into English)
Ole Maaløes Vej 3, DK-2200
Copenhagen N
Denmark
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT LIST
Exhibit |
| Description |
99.1 |
| |
99.2 |
| |
99.3 |
| Appendix 1 to Notice to convene Extraordinary General Meeting (candidate for director) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
| Orphazyme A/S | ||||
|
|
|
| |||||
Date: January 25, 2022 |
|
|
| By: |
| /s/ Anders Vadsholt | ||
|
|
|
|
|
| Name |
| Anders Vadsholt |
|
|
|
|
|
| Title: |
| Chief Financial Officer |